Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF) (2020 - 2023)

Historic Depreciation & Amortization (CF) for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $77000.0.

  • Cullinan Therapeutics' Depreciation & Amortization (CF) rose 3050.85% to $77000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $310000.0, marking a year-over-year increase of 23333.33%. This contributed to the annual value of $306000.0 for FY2024, which is 129.03% down from last year.
  • Per Cullinan Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $77000.0 for Q4 2023, which was up 3050.85% from $80000.0 recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Depreciation & Amortization (CF) peaked at $81000.0 during Q2 2023, and registered a low of $9000.0 during Q3 2022.
  • Its 4-year average for Depreciation & Amortization (CF) is $32375.0, with a median of $15000.0 in 2020.
  • In the last 5 years, Cullinan Therapeutics' Depreciation & Amortization (CF) tumbled by 3076.92% in 2022 and then soared by 78888.89% in 2023.
  • Over the past 4 years, Cullinan Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $15000.0 in 2020, then dropped by 20.0% to $12000.0 in 2021, then soared by 391.67% to $59000.0 in 2022, then surged by 30.51% to $77000.0 in 2023.
  • Its Depreciation & Amortization (CF) stands at $77000.0 for Q4 2023, versus $80000.0 for Q3 2023 and $81000.0 for Q2 2023.